Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Dermatology

Standard of Care Treatment for GPP Flares and Maintenance

At a Glance

Generalized pustular psoriasis treatment has two phases: urgent care to control a potentially dangerous flare, often with spesolimab given through a vein and hospital support, followed by maintenance treatment to reduce future flares.

Because Generalized Pustular Psoriasis (GPP) is a systemic disease, treatment is divided into two distinct goals: stopping an active, potentially dangerous flare and preventing future flares from occurring. Your medical team will tailor your treatment based on your age, overall health, and how frequently your symptoms return [1].

Phase 1: Treating an Acute Flare

When you are in the middle of a flare, the priority is to clear the pustules and calm the systemic inflammation as quickly as possible. Approximately 50% of significant flares are severe enough to require hospitalization for monitoring and intensive treatment [2]. Hospital care may include fluid and electrolyte replacement, temperature regulation, intensive wound and skin care, pain control, and evaluation for infection [2].

Targeted Therapy: Spesolimab (Spevigo)

Spesolimab is the first therapy specifically designed to block the IL-36 pathway, which drives GPP inflammation [3]. For an acute flare, it is given as a single 900-mg dose through an intravenous (IV) infusion [3].

  • Effectiveness: In clinical trials (Effisayil 1), 54% of patients had no visible pustules one week after a single dose, compared to 6% in the placebo group [3].
  • Follow-up: If pustules are still present after one week, your doctor may give a second IV dose depending on the clinical protocol [4].
  • Risks: The most common side effects are infections and potential hypersensitivity or allergic-like reactions to the infusion [3][2]. Dosing and approved ages vary by country and label.

Conventional Flare Treatments

If targeted therapy is not available or appropriate, doctors may use “conventional” systemic medications. These are often used “off-label,” meaning they were originally approved for other types of psoriasis or conditions [5]:

  • Cyclosporine: Works quickly to suppress the immune system but requires close monitoring of blood pressure and kidney function [6][7].
  • Infliximab: A biologic given by IV that can work rapidly, though in rare cases it has been known to paradoxically trigger a GPP flare [8][9].

Important Note on Systemic Corticosteroids: Never start, stop, or taper systemic corticosteroids (like prednisone) on your own. Abruptly stopping a steroid is a known precipitant of severe GPP flares. While they are generally not routine first-line treatments due to this withdrawal risk, specialists may still use them in carefully selected severe or pregnancy-associated situations under a highly supervised tapering plan [10][2].

Phase 2: Maintenance and Prevention

Once your skin is clear, the focus shifts to maintenance. This is especially important for patients with the “relapsing” form of GPP [1].

Long-Term Targeted Therapy

Subcutaneous (SC) spesolimab (an injection under the skin) is used to prevent flares in approved jurisdictions. In a 48-week study (Effisayil 2), patients receiving maintenance regimens experienced significantly lower flare rates (e.g., 10%) compared to those in the placebo group (52%) [11]. You must follow your prescriber’s specific instructions regarding loading doses and intervals as these vary by product label.

Conventional Maintenance Options

Conventional drugs are not interchangeable and require specific monitoring and safety requirements:

Medication How it Works Key Monitoring/Harms
Acitretin An oral retinoid (vitamin A derivative) [12]. Can cause high cholesterol/lipids and must be strictly avoided in pregnancy due to severe birth defect risks [13][14].
Methotrexate An oral or injectable immune-suppressor [15]. Requires regular blood tests (e.g., CBC and liver tests) to check for liver toxicity and low blood cell counts [13][8].
Other Biologics Drugs like ixekizumab or secukinumab (IL-17 inhibitors) [16]. Used when other treatments fail; requires monitoring and screening for infections like tuberculosis [17].

Future Directions

Research is ongoing for new targeted treatments. One promising candidate is imsidolimab, another antibody that blocks the IL-36 receptor [18]. In Phase 3 trials (GEMINI-1), a single IV dose helped over half of the patients achieve clear skin within four weeks [18][19]. It is important to note that imsidolimab is an investigational treatment and may not yet be approved as standard care in your jurisdiction [20].

Common questions in this guide

How is a serious generalized pustular psoriasis flare treated?
The immediate goal is to clear pustules and calm whole-body inflammation quickly. Spesolimab (Spevigo) may be given as a single 900-mg infusion into a vein when appropriate, while severe flares may require hospital care for fluids, temperature control, skin and wound care, pain relief, and infection evaluation.
What should I expect if the first spesolimab dose does not clear my pustules?
Your doctor may consider a second infusion about one week later if pustules remain, depending on the treatment protocol and local product instructions. Do not arrange an extra dose or change treatment without your medical team's direction.
Can I stop prednisone or another steroid when a GPP flare improves?
No. Never start, stop, or taper a systemic corticosteroid such as prednisone on your own, because abrupt withdrawal can trigger a severe GPP flare. If a specialist uses a steroid in a selected situation, they should provide a closely supervised tapering plan.
What treatments can help prevent future GPP flares?
Where approved, subcutaneous spesolimab can be used between flares to lower the chance of another flare. Other maintenance options include acitretin, methotrexate, and some biologic medicines, but the best choice depends on your health, pregnancy plans, previous treatment response, and required monitoring.
What safety tests are needed for GPP medicines?
Cyclosporine requires monitoring of blood pressure and kidney function. Methotrexate usually requires regular blood counts and liver tests, acitretin can affect blood fats and must be avoided in pregnancy, and some biologics require infection screening such as tuberculosis testing.
Is imsidolimab an available standard treatment for GPP?
Imsidolimab is an investigational antibody that blocks the IL-36 receptor. It may not be approved as standard treatment in your country, so ask your specialist about its current status and whether any clinical trial options are appropriate.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the severity of my flares, am I a candidate for targeted therapy with spesolimab?
  2. 2.What is our plan for a second IV dose if my pustules don't clear within the first week after treatment?
  3. 3.If we use conventional therapy like methotrexate or acitretin, what specific blood tests will I need and how often?
  4. 4.How will we decide when it is time to move from treating an active flare to starting maintenance therapy?
  5. 5.What is our plan for supportive hospital care, such as hydration, wound care, and pain management, if I experience a severe flare?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Generalized Pustular Psoriasis: Review and Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology.

    Puig L, Carrascosa JM, Rivera R, et al.

    Actas dermo-sifiliograficas 2026; (117(3)):104544 doi:10.1016/j.ad.2025.104544.

    PMID: 41371399
  2. 2

    Clinical Course and Characteristics of Generalized Pustular Psoriasis.

    Choon SE, Navarini AA, Pinter A

    American journal of clinical dermatology 2022; (23(Suppl 1)):21-29 doi:10.1007/s40257-021-00654-z.

    PMID: 35061227
  3. 3

    Trial of Spesolimab for Generalized Pustular Psoriasis.

    Bachelez H, Choon SE, Marrakchi S, et al.

    The New England journal of medicine 2021; (385(26)):2431-2440 doi:10.1056/NEJMoa2111563.

    PMID: 34936739
  4. 4

    Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.

    Elewski BE, Lebwohl MG, Anadkat MJ, et al.

    Journal of the American Academy of Dermatology 2023; (89(1)):36-44 doi:10.1016/j.jaad.2023.02.040.

    PMID: 36870370
  5. 5

    2023 guidelines on the management of psoriasis by the Dermatological Society of Singapore.

    Oon HH, Tan C, Aw DCW, et al.

    Annals of the Academy of Medicine, Singapore 2024; (53(9)):562-577 doi:10.47102/annals-acadmedsg.2023367.

    PMID: 39373375
  6. 6

    A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics, Clinical Characteristics, and Management of Generalized Pustular Psoriasis Patients in Spain: IMPULSE Study.

    Puig L, Izu Belloso R, Rivera-Díaz R, et al.

    Dermatology (Basel, Switzerland) 2024; (240(5-6)):778-792 doi:10.1159/000540019.

    PMID: 39019021
  7. 7

    Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

    Megna M, Camela E, Ruggiero A, et al.

    Clinical, cosmetic and investigational dermatology 2023; (16()):1677-1690 doi:10.2147/CCID.S407812.

    PMID: 37404368
  8. 8

    Generalized Pustular Psoriasis as a Systemic Inflammatory Disease: Experience With 38 Japanese Cases Over 15 Years at a Single Institution.

    Kikuchi N, Kusano M, Yamamoto T

    Cureus 2025; (17(7)):e88108 doi:10.7759/cureus.88108.

    PMID: 40821152
  9. 9

    Generalized pustular psoriasis: a review and update on treatment.

    Hoegler KM, John AM, Handler MZ, Schwartz RA

    Journal of the European Academy of Dermatology and Venereology : JEADV 2018; (32(10)):1645-1651 doi:10.1111/jdv.14949.

    PMID: 29573491
  10. 10

    A brief guide to pustular psoriasis for primary care providers.

    Crowley JJ, Pariser DM, Yamauchi PS

    Postgraduate medicine 2021; (133(3)):330-344 doi:10.1080/00325481.2020.1831315.

    PMID: 33118424
  11. 11

    Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.

    Morita A, Strober B, Burden AD, et al.

    Lancet (London, England) 2023; (402(10412)):1541-1551 doi:10.1016/S0140-6736(23)01378-8.

    PMID: 37738999
  12. 12

    Current management of generalized pustular psoriasis.

    Kodali N, Blanchard I, Kunamneni S, Lebwohl MG

    Experimental dermatology 2023; (32(8)):1204-1218 doi:10.1111/exd.14765.

    PMID: 36779681
  13. 13

    Clinical analysis of generalized pustular psoriasis in Chinese patients: A retrospective study of 110 patients.

    Zheng J, Chen W, Gao Y, et al.

    The Journal of dermatology 2021; (48(9)):1336-1342 doi:10.1111/1346-8138.15958.

    PMID: 34018629
  14. 14

    Successful treatment of generalized pustular psoriasis with chronic hepatitis B using spesolimab: A case report.

    Ming R, Zhang L, Xiong X

    Medicine 2025; (104(17)):e41979 doi:10.1097/MD.0000000000041979.

    PMID: 40295264
  15. 15

    Review of treatments for generalized pustular psoriasis.

    Kearns DG, Chat VS, Zang PD, et al.

    The Journal of dermatological treatment 2021; (32(5)):492-494 doi:10.1080/09546634.2019.1682502.

    PMID: 31697211
  16. 16

    Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).

    Okubo Y, Mabuchi T, Iwatsuki K, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2019; (33(2)):325-332 doi:10.1111/jdv.15287.

    PMID: 30317671
  17. 17

    Monotherapy with Biologics for Generalized Pustular Psoriasis: A Systematic Review of Comparative Interventional Studies with an Exploratory Network Meta-Analysis.

    Gupta AK, Bamimore MA, Wang T, et al.

    Medical sciences (Basel, Switzerland) 2026; (14(2)) doi:10.3390/medsci14020307.

    PMID: 42346846
  18. 18

    Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis.

    Smieszek S, Przychodzen B, Tyner C, et al.

    NEJM evidence 2026; (5(5)):EVIDoa2500272 doi:10.1056/EVIDoa2500272.

    PMID: 42047557
  19. 19

    Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial.

    Warren RB, Reich A, Kaszuba A, et al.

    The British journal of dermatology 2023; (189(2)):161-169 doi:10.1093/bjd/ljad083.

    PMID: 37120722
  20. 20

    Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease.

    Iznardo H, Puig L

    International journal of molecular sciences 2021; (22(9)) doi:10.3390/ijms22094344.

    PMID: 33919434

This page explains treatment options for generalized pustular psoriasis flares and maintenance for informational purposes only and does not constitute medical advice. Your treating medical team should guide medication choice, dosing, monitoring, and any steroid changes.

Get notified when new evidence is published on Generalized pustular psoriasis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.